Citi analyst Neena Bitritto-Garg lowered the firm’s price target on Neurocrine to $127 from $131 and keeps a Buy rating on the shares ahead of the Q1 results. The analyst sees a potential weak Ingrezza quarter for Neurocrine as sell-side estimates "appear too high given seasonal dynamics."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBIX: